Dermatology
SR | Silicone gel sheeting for treating keloid scars
15 Feb, 2023 | 15:53h | UTCSilicone gel sheeting for treating keloid scars – Cochrane Library
Phase 2 RCT | Effects of Difelikefalin in notalgia paresthetica
13 Feb, 2023 | 12:42h | UTCPhase 2 Trial of Difelikefalin in Notalgia Paresthetica – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Phase 2 Trial Finds Difelikefalin Could Prove Useful in Notalgia Paresthetica – HCP Live
Difelikefalin Improves Itch Intensity in Notalgia Paresthetica – HealthDay
Commentary on Twitter
In a phase 2 trial in notalgia paresthetica, oral difelikefalin treatment resulted in modestly reduced itch as compared with placebo. https://t.co/MQMO7z4o0W pic.twitter.com/2iaCgb3c93
— NEJM (@NEJM) February 8, 2023
Brief Review | Mpox — A rapidly evolving disease
10 Feb, 2023 | 13:56h | UTCMpox—A Rapidly Evolving Disease – JAMA Dermatology
Related:
Monkeypox (hMPXV infection): A practical review – American Journal of Medicine
WHO renames “monkeypox” as “mpox” to help destigmatize the disease.
Study shows there is substantial monkeypox transmission before symptoms appear.
Monkeypox – New England Journal of Medicine
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
RCT | Tissue adhesive, adhesive tape, and sutures for skin closure of pediatric surgical wounds
9 Feb, 2023 | 13:35h | UTC
Review | Pyoderma gangrenosum: Established and emerging pharmacological treatments
8 Feb, 2023 | 12:27h | UTC
Phase 2b RCT | An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis
8 Feb, 2023 | 12:22h | UTCAn anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study – The Lancet (link to abstract – $ for full-text)
News Release: New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results – Mount Sinai Health System
Commentary: Rocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis – HealthDay
Commentary on Twitter:
Just published in The Lancet: Patients treated w- rocatinlimab, an anti-OX40 antibody, had progressive improvements in atopic dermatitis, which was maintained in most pts after treatment stopped. @EmmaGuttman PI. Details: https://t.co/PpiKsy0ra0 pic.twitter.com/6ghKpsLQsZ
— Mount Sinai Dermatology (@MSHSDerm) December 10, 2022
Guideline | Urticaria management
6 Feb, 2023 | 13:25h | UTC
RCT | Oral minocycline plus rifampicin vs. oral linezolid for complicated skin and skin structure infections caused by MRSA
2 Feb, 2023 | 14:33h | UTC
Syphilis in dermatology: recognition and management
31 Jan, 2023 | 14:01h | UTCSyphilis in Dermatology: Recognition and Management – American Journal of Clinical Dermatology (if the link is paywalled, try this one in PMC)
Review | Skin infections due to Panton-Valentine Leukocidin–producing S. aureus
31 Jan, 2023 | 13:44h | UTC
Consensus Paper | Management of pemphigus
20 Jan, 2023 | 14:39h | UTC
Consensus Paper | Revision of classification system for reporting on skin biopsies of melanocytic lesions
15 Jan, 2023 | 20:17h | UTCCommentaries:
MPATH-Dx Version 2.0 Simplifies Classification of Melanoma – HealthDay
Commentary on Twitter
American and international #dermatopathologists revise Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema. MPATH-Dx V2.0 improves standardized diagnostic reporting and patient management of #melanoma. https://t.co/G0fluzq5fs
— JAMA Network Open (@JAMANetworkOpen) January 12, 2023
RCT | Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis
15 Jan, 2023 | 20:07h | UTC
Commentary on Twitter
Does blocking the IL-13 cytokine w/ lebrikizumab combined w/ topical therapy provide clinical benefit in atopic eczema? This study reflecting real-world use patterns suggests a benefit. https://t.co/apUvYO3Jqv
— JAMA Dermatology (@JAMADerm) January 13, 2023
Retrospective Study | Clinical features and management of individuals admitted to hospital with monkeypox
13 Jan, 2023 | 13:33h | UTC
Monkeypox (hMPXV infection): a practical review
11 Jan, 2023 | 14:25h | UTCMonkeypox (hMPXV infection): A practical review – American Journal of Medicine
WHO Interim Guidance | Surveillance, case investigation and contact tracing for mpox (monkeypox)
10 Jan, 2023 | 14:45h | UTC
Atypical ulcers: a stepwise approach for clinicians
10 Jan, 2023 | 14:00h | UTCAtypical Ulcers: A Stepwise Approach for Clinicians – Wounds
Intrapatient RCT | Beremagene Geperpavec (B-VEC) vs. placebo for dystrophic epidermolysis bullosa.
16 Dec, 2022 | 13:34h | UTCTrial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa – New England Journal of Medicine (link to abstract – $ for full-text)
RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.
12 Dec, 2022 | 12:40h | UTCMepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
SR | Skin care interventions in infants for preventing eczema and food allergy.
12 Dec, 2022 | 12:23h | UTCSkin care interventions in infants for preventing eczema and food allergy – Cochrane Library
Summary: Skin care interventions for preventing eczema and food allergy – Cochrane Library
Commentary on Twitter
Read our newest review on skin care interventions in infants for preventing eczema and food allergy! https://t.co/o8HtBXRVM5 pic.twitter.com/BPzsjJZvTf
— Cochrane Skin (@CochraneSkin) November 15, 2022
M-A | Allergen immunotherapy for atopic dermatitis.
9 Dec, 2022 | 13:24h | UTC
Cohort Study | Cutaneous involvement in catastrophic antiphospholipid syndrome.
8 Dec, 2022 | 12:53h | UTCCutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients – JAMA Dermatology (free for a limited period)
Commentary on Twitter
In this cohort study, half of patients with catastrophic APS (CAPS) showed cutaneous involvement, with a spectrum of clinical presentations, including distal inflammatory edema. Skin biopsies confirmed diagnosis in all but 1 biopsied patient. https://t.co/lwBL3lyLxT
— JAMA Dermatology (@JAMADerm) December 7, 2022
RCT | Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment.
7 Dec, 2022 | 14:29h | UTC
Monkeypox in pregnancy: virology, clinical presentation, and obstetric management.
6 Dec, 2022 | 13:58h | UTCRelated:
WHO renames “monkeypox” as “mpox” to help destigmatize the disease.
Study shows there is substantial monkeypox transmission before symptoms appear.
Monkeypox – New England Journal of Medicine
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
WHO renames “monkeypox” as “mpox” to help destigmatize the disease.
29 Nov, 2022 | 14:27h | UTCWHO recommends new name for monkeypox disease – World Health Organization
Commentaries:
WHO to phase out the name ‘monkeypox’ for ‘mpox’ – STAT
WHO renames monkeypox as mpox, citing racist stigma – NPR
The Future of Monkeypox – The Atlantic
Monkeypox given new name by global health experts – BBC
Monkeypox to be renamed mpox to avoid stigma, says WHO – The Guardian
Commentary on Twitter (thread – click for more)
Following consultations, WHO will begin using a new term for “#monkeypox” disease: '#mpox'.
Both names will be used simultaneously for one year while 'monkeypox' is phased out https://t.co/VT9DAdYrGY pic.twitter.com/Ae6zgkefPI— World Health Organization (WHO) (@WHO) November 28, 2022